Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the sepsis drug market will provide significant opportunity for drug developers over the next ten years according to a new Pharmacor study entitled Sepsis and Septic Shock. Sepsis, historically dubbed "the graveyard of drug development," has been associated with high risk because of numerous failures in late-stage trials. However, improvements in the understanding of sepsis and in clinical trial design have the potential to deliver effective drugs to the market in the coming decade. Eli Lilly's novel therapy Xigris (drotrecogin alfa), the first marketed therapy to directly target the inflammatory and coagulation abnormalities associated with sepsis, will open and expand the market for emerging therapies that target this indication.
"Xigris will drive market growth over the next decade," said Jason LaBonte, analyst, Decision Resources. "However, the agent's use is still limited and tremendous opportunity remains for any company that can successfully develop a product to serve the vast unmet needs in this market. Despite the advances provided by Xigris, severe sepsis and septic shock are still associated with high mortality and significant expense."
Sepsis and septic shock are leading causes of morbidity and mortality among hospitalized patients. In the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), we estimate that there are more than 2 million cases of sepsis every year. Of these cases, most are eventually treated in an intensive care unit, and 400,000 to 500,000 result in death.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Sepsis and Septic Shock is an Infectious Disease study.
About Decision Resources
Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall for Decision Resources, Inc.,
Web site: http://www.decisionresources.com/